Secondary Acute Myeloid Leukemia Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Secondary Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia+1 more
City of Hope Medical Center27 enrolled1 locationNCT05672147
Recruiting
Phase 1

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+15 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT03630991
Recruiting
Phase 1Phase 2

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+11 more
Fred Hutchinson Cancer Center36 enrolled1 locationNCT06928662
Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 1

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome+2 more
Jennifer Saultz51 enrolled3 locationsNCT03874052
Recruiting
Phase 2

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia
University of Michigan Rogel Cancer Center20 enrolled1 locationNCT05780879
Recruiting
Phase 1Phase 2

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaSecondary Acute Myeloid Leukemia
Heinrich-Heine University, Duesseldorf38 enrolled6 locationsNCT05807932
Recruiting
Phase 1Phase 2

Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML

Myelodysplastic SyndromesChronic Myelomonocytic Leukemia-2Secondary Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT05584761